Posted by Michael Wonder on 27 Apr 2022
Health Canada approves Vraylar (cariprazine) for the treatment of bipolar l disorder and schizophrenia in adults
27 April 2022 - Vraylar is a new atypical antipsychotic medication with partial agonist activity at central dopamine D3 receptors in addition to targeted activity at D2 and serotonin 5-HT1A and 5-HT2A receptors.
AbbVie announced today that Health Canada has approved Vraylar (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar l disorder in adults, as well as the treatment of schizophrenia in adults.
